Myelodysplastic/Myeloproliferative Neoplasm

Myelodysplastic/Myeloproliferative Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 70
Ph III recruiting: 3
Growth YoY: —
Industry share: 16%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (77)

clinicaltrialsPublishedShowing 1–27 of 27 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05201066	Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.	active not recruiting	Phase 2	33	Novartis PharmaceuticalsINDUSTRY	15	Sep 22, 2026	clinicaltrials
NCT04734990	Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	active not recruiting	Phase 1 / Phase 2	24	M.D. Anderson Cancer CenterOTHER	1	Sep 18, 2026